HRP20210572T1 - Kombinacijsko liječenje raka - Google Patents
Kombinacijsko liječenje raka Download PDFInfo
- Publication number
- HRP20210572T1 HRP20210572T1 HRP20210572TT HRP20210572T HRP20210572T1 HR P20210572 T1 HRP20210572 T1 HR P20210572T1 HR P20210572T T HRP20210572T T HR P20210572TT HR P20210572 T HRP20210572 T HR P20210572T HR P20210572 T1 HRP20210572 T1 HR P20210572T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- hormonal agent
- group
- vrac modulator
- use according
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 12
- 201000011510 cancer Diseases 0.000 title claims 12
- 238000011284 combination treatment Methods 0.000 title 1
- 239000013059 antihormonal agent Substances 0.000 claims 20
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 10
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 5
- 229960002258 fulvestrant Drugs 0.000 claims 5
- 229960001603 tamoxifen Drugs 0.000 claims 5
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 claims 4
- RCOWGILQXUPXEW-FUSOFXSQSA-N (8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-[(z)-3-hydroxyprop-1-enyl]-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@@]2(O)\C=C/CO)[C@]2(C)C1 RCOWGILQXUPXEW-FUSOFXSQSA-N 0.000 claims 4
- RTCKAOKDXNYXEH-FWSJOHTJSA-N Aglepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)\C=C/C)=CC=C(N(C)C)C=C1 RTCKAOKDXNYXEH-FWSJOHTJSA-N 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 229950008045 aglepristone Drugs 0.000 claims 4
- 229940046836 anti-estrogen Drugs 0.000 claims 4
- 230000001833 anti-estrogenic effect Effects 0.000 claims 4
- 229960003608 clomifene Drugs 0.000 claims 4
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims 4
- 239000000328 estrogen antagonist Substances 0.000 claims 4
- 102000015694 estrogen receptors Human genes 0.000 claims 4
- 108010038795 estrogen receptors Proteins 0.000 claims 4
- 229950001701 lilopristone Drugs 0.000 claims 4
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims 4
- 229960003248 mifepristone Drugs 0.000 claims 4
- 229950011093 onapristone Drugs 0.000 claims 4
- 239000000583 progesterone congener Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 claims 4
- 229960000499 ulipristal acetate Drugs 0.000 claims 4
- 102100032187 Androgen receptor Human genes 0.000 claims 3
- 108010080146 androgen receptors Proteins 0.000 claims 3
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 3
- 229960005026 toremifene Drugs 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003388 anti-hormonal effect Effects 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 239000003418 antiprogestin Substances 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000003623 progesteronic effect Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005969 steroid hormone receptors Human genes 0.000 claims 1
- 108020003113 steroid hormone receptors Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. VRAC modulator formule I
[image]
ili njegova farmaceutski prihvatljiva sol,
i anti-hormonski agens za uporabu u liječenju raka,
pri čemu je hormonski agens odabran iz skupine koja se sastoji od:
a. anti-estrogena odabranog iz skupine koja se sastoji od: fulvestranta, tamoksifena, toremifena, i klomifena, i
b. anti-progestogena odabranog iz skupine koja se sastoji od: mifepristona, ulipristalnog acetata, aglepristona, lilopristona i onapristona.
2. VRAC modulator i anti-hormonski agens za uporabu sukladno zahtjevu 1, pri čemu je anti-hotmonski agens fulvestrant.
3. VRAC modulator i anti-hormonski agens za uporabu sukladno zahtjevu 1, pri čemu je anti-hotmonski agens tamoksifen.
4. VRAC modulator i anti-hormonski agens za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu je rak otporan na anti-hormonski agens.
5. VRAC modulator i anti-hormonski agens za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu je rak metastatski.
6. VRAC modulator i anti-hormonski agens za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu je rak odabran iz skupine koju čine rak dojke, rak prostate, rak grlića maternice i rak maternice.
7. VRAC modulator i anti-hormonski agens za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu je rak rak dojke.
8. VRAC modulator i anti-hormonski agens za uporabu prema zahtjevu 7, pri čemu je rak dojke metastatski rak dojke.
9. VRAC modulator i anti-hormonski agens za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu je rak steroidni hormon receptor pozitivan rak, odabran iz skupine koja se sastoji od: estrogen receptor (ER) pozitivnog raka, kao što su ER pozitivan rak dojke ili ER pozitivan rak maternice; pozitivan rak progestogenog receptora (PR), kao što je PR pozitivan rak dojke; i androgeni receptor (AR) pozitivan rak, kao što je AR pozitivan rak prostate.
10. VRAC modulator i anti-hormonski agens za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu je VRAC modulator administriran prije i/ili istovremeno s i/ili nakon početka antikancerske terapije.
11. VRAC modulator i anti-hormonski agens za uporabu sukladno bilo kojem od prethodnih zahtjeva pri čemu je VRAC modulator:
a. u obliku tableta ili kapsula za oralnu primjenu; ili
b. u tekućem obliku ili za intravenozne primjene ili kontinuirane infuzije
12. Farmaceutski pripravak koji sadrži efikasnu količinu VRAC modulatora formule I
[image]
ili njegovu farmaceutski prihvatljivu sol, i
anti-hormonski agens i jedan ili više farmaceutski prihvatljivih adjuvansa,
pomoćnih tvari, nosača, pufera i/ili razrjeđivača,
pri čemu je anti-hormonski agens izabran iz skupine koja se sastoji od:
a. anti-estrogena koji je odabran iz skupine koja se sastoji od: fulvestranta, tamoksifena, tormifena, i klomifena, i
b. anti-progesterona odabranog iz skupine koja se sastoji od: mifepristona, ulipristal acetata, aglepristona, lilopristona i onapristona.
13. Farmaceutski pripravak koji sadrži efikasnu količinu VRAC modulatora formule I
[image]
ili njegovu farmaceutski prihvatljivu sol,
i
efikasnu količinu anti-hormonskog sredstva za primjenu kao lijek,
pri čemu se anti-hormonsko sredstvo odabire iz skupine koja se sastoji od:
a. anti-estrogena odabranog iz skupine koja se sastoji od: fulvestranta, tamoksifena, toremifena i clomifena i
b. anti-progestogena odabranog iz skupine koja se sastoji od: mifepristona, ulipristalnog acetata, aglepristona, lilopristona i onapristona.
14. Set dijelova koji sadrži VRAC modulator formule I
[image]
ili njegovu farmaceutski prihvatljivu sol, i
anti-hormonsko sredstvo za primjenu kao lijek, pri čemu se anti-hormonsko sredstvo odabire iz skupine koja se sastoji od:
a. anti-estrogena odabranog iz skupine koja se sastoji od: fulvestranta, tamoksifena, toremifena i klomifena i
b. anti-progestogena odabranog iz skupine koja se sastoji od: mifepristona, ulipristalnog acetata, aglepristona, lilopristona i onapristona.i
pri čemu su VRAC modulator i anti-hormonski agens formulirani za istovremenu, sekvencijalnu ili odvojenu primjenu i opcionalno uputstvo za uporabu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201670325 | 2016-05-17 | ||
| EP19205104.3A EP3622953B1 (en) | 2016-05-17 | 2017-05-17 | Combination treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210572T1 true HRP20210572T1 (hr) | 2021-05-14 |
Family
ID=58800797
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200076TT HRP20200076T1 (hr) | 2016-05-17 | 2020-01-17 | Kombinacijsko liječenje raka |
| HRP20210572TT HRP20210572T1 (hr) | 2016-05-17 | 2021-04-09 | Kombinacijsko liječenje raka |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200076TT HRP20200076T1 (hr) | 2016-05-17 | 2020-01-17 | Kombinacijsko liječenje raka |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11103481B2 (hr) |
| EP (3) | EP3854393A1 (hr) |
| JP (1) | JP7033554B2 (hr) |
| CN (1) | CN109475535A (hr) |
| AU (1) | AU2017266724B2 (hr) |
| BR (1) | BR112018073518A2 (hr) |
| CA (1) | CA3023202A1 (hr) |
| CY (2) | CY1122541T1 (hr) |
| DK (2) | DK3458052T3 (hr) |
| ES (2) | ES2770374T3 (hr) |
| HR (2) | HRP20200076T1 (hr) |
| HU (2) | HUE053744T2 (hr) |
| LT (2) | LT3458052T (hr) |
| PL (2) | PL3622953T3 (hr) |
| PT (2) | PT3622953T (hr) |
| RS (2) | RS61786B1 (hr) |
| SI (2) | SI3458052T1 (hr) |
| WO (1) | WO2017198700A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017266724B2 (en) * | 2016-05-17 | 2022-04-14 | Scandion Oncology A/S | Combination treatment of cancer |
| US11530181B2 (en) | 2018-02-22 | 2022-12-20 | University Of Florida Research Foundation, Incorporated | IL-6 inhibitors and methods of treatment |
| EP3846802A1 (en) * | 2018-09-06 | 2021-07-14 | Scandion Oncology A/S | Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1 |
| WO2020079051A1 (en) | 2018-10-16 | 2020-04-23 | Scandion Oncology A/S | Compounds for treatment of microbial infection |
| EP4355323A1 (en) | 2021-06-14 | 2024-04-24 | Scandion Oncology A/S | Combination treatments for cancer patients and methods for identifying same |
| AU2022293969A1 (en) | 2021-06-14 | 2023-12-14 | Scandion Oncology A/S | Methods of increasing the plasma drug exposure of anticancer agents |
| EP4104834A1 (en) | 2021-06-14 | 2022-12-21 | Scandion Oncology A/S | Combination treatments for cancer patients and methods for identifying same |
| TW202321205A (zh) | 2021-07-16 | 2023-06-01 | 丹麥商斯坎丁腫瘤公司 | Sco-101的熱力穩定形式 |
| EP4197525A1 (en) | 2021-12-20 | 2023-06-21 | Scandion Oncology A/S | Combination of drugs for the treatment of cancer |
| CN117229258A (zh) * | 2022-06-07 | 2023-12-15 | 杭州壹瑞医药科技有限公司 | N-四唑基芳基脲类衍生物及其制备方法和应用 |
| WO2023242235A1 (en) | 2022-06-14 | 2023-12-21 | Scandion Oncology A/S | Abcg2 inhibitor and nae inhibitor for the treatment of cancer |
| WO2024013058A1 (en) | 2022-07-11 | 2024-01-18 | Scandion Oncology A/S | Salts of sco-101 and methods involving salts |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| ES2205472T3 (es) | 1997-04-22 | 2004-05-01 | Neurosearch A/S | Derivados de fenilo sustituidos, su preparacion y uso. |
| CA2342626A1 (en) | 1998-10-22 | 2000-05-04 | Neurosearch A/S | Substituted phenyl derivatives, their preparation and use |
| KR20050026091A (ko) | 2002-08-01 | 2005-03-14 | 뉴로서치 에이/에스 | 항혈관형성 요법에 반응하는 질환의 치료에 유용한 화합물 |
| BRPI0410576A (pt) | 2003-06-17 | 2006-06-20 | Neurosearch As | composto quìmico, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo de animal vivo |
| DE602005015682D1 (de) | 2004-02-04 | 2009-09-10 | Neurosearch As | Dimere azacyclische verbindungen und deren verwendung |
| MX2007007029A (es) | 2004-12-17 | 2007-08-08 | Neurosearch As | Derivados de difenilurea utiles como activadores del canal de potasio. |
| CA2646336A1 (en) | 2006-03-14 | 2007-09-20 | Neurosearch A/S | Diphenylurea derivatives and their use as chloride channel blockers or bkca channel modulators |
| PA8852901A1 (es) * | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| TWI508954B (zh) * | 2012-04-27 | 2015-11-21 | Nat Defense Medical Ct | 雜環融合蒽醌衍生物、其製備方法與醫藥組合物 |
| EP2919009B1 (en) | 2014-03-10 | 2018-09-19 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | LRRC8 proteins and protein complexes and methods for identification of channel modulators |
| EP3064207B1 (en) | 2015-03-04 | 2017-12-20 | Scandion Oncology A/S | 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments |
| AU2017266724B2 (en) * | 2016-05-17 | 2022-04-14 | Scandion Oncology A/S | Combination treatment of cancer |
-
2017
- 2017-05-17 AU AU2017266724A patent/AU2017266724B2/en active Active
- 2017-05-17 LT LTEP17726573.3T patent/LT3458052T/lt unknown
- 2017-05-17 DK DK17726573.3T patent/DK3458052T3/da active
- 2017-05-17 ES ES17726573T patent/ES2770374T3/es active Active
- 2017-05-17 SI SI201730169T patent/SI3458052T1/sl unknown
- 2017-05-17 SI SI201730713T patent/SI3622953T1/sl unknown
- 2017-05-17 EP EP21162597.5A patent/EP3854393A1/en active Pending
- 2017-05-17 HU HUE19205104A patent/HUE053744T2/hu unknown
- 2017-05-17 JP JP2018560218A patent/JP7033554B2/ja active Active
- 2017-05-17 CA CA3023202A patent/CA3023202A1/en active Pending
- 2017-05-17 CN CN201780043536.3A patent/CN109475535A/zh active Pending
- 2017-05-17 ES ES19205104T patent/ES2870805T3/es active Active
- 2017-05-17 EP EP17726573.3A patent/EP3458052B1/en active Active
- 2017-05-17 EP EP19205104.3A patent/EP3622953B1/en active Active
- 2017-05-17 PL PL19205104T patent/PL3622953T3/pl unknown
- 2017-05-17 LT LTEP19205104.3T patent/LT3622953T/lt unknown
- 2017-05-17 BR BR112018073518-3A patent/BR112018073518A2/pt active Search and Examination
- 2017-05-17 PT PT192051043T patent/PT3622953T/pt unknown
- 2017-05-17 US US16/302,195 patent/US11103481B2/en active Active
- 2017-05-17 RS RS20210510A patent/RS61786B1/sr unknown
- 2017-05-17 DK DK19205104.3T patent/DK3622953T3/da active
- 2017-05-17 HU HUE17726573A patent/HUE047542T2/hu unknown
- 2017-05-17 PL PL17726573T patent/PL3458052T3/pl unknown
- 2017-05-17 PT PT177265733T patent/PT3458052T/pt unknown
- 2017-05-17 RS RS20200088A patent/RS59844B1/sr unknown
- 2017-05-17 WO PCT/EP2017/061823 patent/WO2017198700A1/en unknown
-
2020
- 2020-01-17 HR HRP20200076TT patent/HRP20200076T1/hr unknown
- 2020-01-27 CY CY20201100070T patent/CY1122541T1/el unknown
-
2021
- 2021-04-09 HR HRP20210572TT patent/HRP20210572T1/hr unknown
- 2021-04-15 CY CY20211100332T patent/CY1124242T1/el unknown
- 2021-07-29 US US17/388,208 patent/US11903927B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210572T1 (hr) | Kombinacijsko liječenje raka | |
| HRP20211124T1 (hr) | TETRAHIDRO-1H-PIRIDO[3,4-b]INDOL ANTI-ESTROGENI LIJEKOVI | |
| ES2704999T3 (es) | Tratamiento de hemorragia por disrupción en regímenes anticonceptivos hormonales prolongados | |
| JP2010180236A5 (hr) | ||
| US3568828A (en) | Modified sequential oral contraceptive | |
| RS53876B1 (en) | PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES AROMATASE AND GESTAGEN BLOCKERS, FOR THE TREATMENT OF ENDOMETRIOSIS | |
| JP2015187157A5 (hr) | ||
| HRP20211879T1 (hr) | Kombinirana terapija za liječenje raka | |
| JP2017039771A5 (hr) | ||
| TW200831107A (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| JP2005538150A5 (hr) | ||
| RU2007101304A (ru) | Модуляторы рецептора прогестерона, содержащие производные пиррол-оксиндола и применение | |
| JP2010508275A5 (hr) | ||
| WO2011073995A2 (en) | Liquid vaginal spray of progesterone | |
| RU2005108977A (ru) | Схема восполнения эстрогена | |
| HRP20240121T1 (hr) | Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine | |
| ES2397983T3 (es) | Procedimiento anticonceptivo oral multifásico de ciclo prolongado | |
| HRP20210418T1 (hr) | Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1 | |
| JP2011507853A5 (hr) | ||
| RU2020121222A (ru) | Агонисты fxr для лечения заболеваний печени | |
| CN101732303B (zh) | 益母草碱用于更年期病症医药用途 | |
| Dezman et al. | Two case of atypical endometrial hyperplasia associated with “bioidentical” hormone replacement therapy: IGCS-0084 Uterine Cancer, including Sarcoma | |
| ES2320662T3 (es) | Hormonoterapia restitutiva y tratamiento para la depresion con dienogest. | |
| CA2248841C (en) | Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy | |
| RU2016116915A (ru) | Комбинация |